Get E&O weekly. | Subscribe
Digital health research from Brian Dolan.
Welcome to E&O.
Last week I wrote about the FDA's posteriorities -- these are one step below priorities -- for 2021, which include risk categories for SaMD and new guidance for devices related to opioid use disorder. I also put together some data on the rapid ascent of telehealth-related comments (76x y-o-y) on the